Patents Assigned to Sunshine Lake Pharma Co., Ltd.
-
Publication number: 20150050239Abstract: The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.Type: ApplicationFiled: July 19, 2013Publication date: February 19, 2015Applicants: Calitor Sciences, LLC, Sunshine Lake Pharma Co., Ltd.Inventors: Ning Xi, Yanjun Wu, Min Liao, Yanming Feng
-
Publication number: 20150037280Abstract: The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.Type: ApplicationFiled: July 19, 2013Publication date: February 5, 2015Applicants: Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLCInventors: Ning Xi, Yanjun Wu, Min Liao, Yanming Feng
-
Patent number: 8937053Abstract: Disclosed herein are a process or method for the preparation of prasugrel and several novel crystalline forms of prasugrel hydrochloride. The process comprises preparation of prasugrel by acetylation in solvents which have low boiling point and/or low toxicity, and the process not only avoids using solvents which have high boiling point and/or high toxicity such as toluene, acetonitrile and so on, but also resolves the problem about thermal instability of prasugrel, and the loss of prasugrel is reduced, as well as the yield is raised. The yield of prasugrel is higher than 85% and the purity is higher than 99.5%. The process can prepare prasugrel and its pharmaceutically acceptable salts. The novel crystalline forms of prasugrel hydrochloride are crystalline form H1, H2 and H3, and their performance in oral absorbability, activating metabolism and inhibiting platelet aggregation is excellent.Type: GrantFiled: June 21, 2012Date of Patent: January 20, 2015Assignees: Sunshine Lake Pharma Co., Ltd., Yichang Changjiang Pharmaceutical Co., Ltd.Inventors: Lijun Li, Hailong Wang, Zhongqing Wang
-
Publication number: 20140371279Abstract: The present invention relates to the field of pharmaceutical chemistry. Disclosed herein is a crystalline form of azilsartan, which is substantially pure. The crystalline form is crystalline form A, form B, form C, form D, form E, form F, form G, form H, form I, form J or form K. The substantially pure crystalline forms of azilsartan of the invention generally have good properties such as high solubility, high bioavailability, good stability, long shelf life and good antistatic property. The crystalline forms of azilsartan generally exhibit an excellent performance in reducing clinical systolic blood pressure (SBP) and average 24-hour SBP. Disclosed herein are methods of preparing the substantially pure crystalline forms of azilsartan, pharmaceutical compositions comprising the crystalline forms, and preparation methods and uses thereof.Type: ApplicationFiled: September 27, 2012Publication date: December 18, 2014Applicants: SUNSHINE LAKE PHARMA CO., LTD., RUYUAN PHARM CO., LTD.Inventors: Xin Lei, Jinan Peng, Tianming Wang, Zhiqing Lv, Wan Li
-
Publication number: 20140364464Abstract: The present invention relates to the field of pharmaceutical chemistry. Disclosed herein is a crystalline form of azilsartan medoxomil potassium, which is substantially pure. The crystalline form is crystalline form A, form B, form C, form D, form E, form F, form G, form H, form I, form J, form K or form L. The substantially pure crystalline forms of azilsartan medoxomil potassium of the invention generally have good properties such as high solubility, high bioavailability, good stability, long shelf life and good antistatic property. The crystalline forms of azilsartan medoxomil potassium generally exhibit an excellent performance in reducing clinical systolic blood pressure (SBP) and average 24-hour SBP. Disclosed herein are methods of preparing the substantially pure crystalline forms of azilsartan medoxomil potassium, pharmaceutical compositions comprising the crystalline forms, and preparation methods and uses thereof.Type: ApplicationFiled: January 14, 2013Publication date: December 11, 2014Applicants: SUNSHINE LAKE PHARMA CO., LTD., RUYUAN HEC PHARM CO., LTD.Inventors: Xin Lei, Zhiqing Lv, Tianming Wang
-
Publication number: 20140234254Abstract: The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (PI3 kinases) and mTOR, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.Type: ApplicationFiled: February 15, 2014Publication date: August 21, 2014Applicants: SUNSHINE LAKE PHARMA CO., LTD., CALITOR SCIENCES, LLCInventor: Ning Xi
-
Publication number: 20140228361Abstract: The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.Type: ApplicationFiled: November 14, 2012Publication date: August 14, 2014Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Jiancun Zhang, Yingjun Zhang, Weihong Zhang, Bing Liu, Jiquan Zhang, Jinlei Liu, Lu Zhang
-
Publication number: 20140206883Abstract: The present invention relates to the field of pharmaceutical chemistry, specifically relates to a statin intermediate having formula I and preparation thereof. The advantages of the method used to prepare the chiral sulfone intermediate having formula I are that a fluorophore is introduced at the beginning of the synthesis, and the intermediates are mostly solid, which enables quality control to be easily carried out.Type: ApplicationFiled: July 19, 2012Publication date: July 24, 2014Applicants: YICHANG CHANGJIANG PHARMACEUTICAL CO., LTD., SUNSHINE LAKE PHARMA CO., LTD.Inventors: Shouhua Zhang, Zhongqing Wang, Zhonghua Luo
-
Publication number: 20140155351Abstract: Disclosed herein are a process or method for the preparation of prasugrel and several novel crystalline forms of prasugrel hydrochloride. The process comprises preparation of prasugrel by acetylation in solvents which have low boiling point and/or low toxicity, and the process not only avoids using solvents which have high boiling point and/or high toxicity such as toluene, acetonitrile and so on, but also resolves the problem about thermal instability of prasugrel, and the loss of prasugrel is reduced, as well as the yield is raised. The yield of prasugrel is higher than 85% and the purity is higher than 99.5%. The process can prepare prasugrel and its pharmaceutically acceptable salts. The novel crystalline forms of prasugrel hydrochloride are crystalline form H1, H2 and H3, and their performance in oral absorbability, activating metabolism and inhibiting platelet aggregation is excellent.Type: ApplicationFiled: June 21, 2012Publication date: June 5, 2014Applicants: YICHANG CHANGJIANG PHARMACEUTICAL CO., LTD, SUNSHINE LAKE PHARMA CO., LTDInventors: Lijun Li, Hailong Wang, Zhongqing Wang
-
Publication number: 20140147412Abstract: Disclosed are spiro compounds of formula (I), or stereomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof. The compounds can be used to treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore disclosed are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions in the treatment of HCV infection or hepatitis C disease.Type: ApplicationFiled: July 9, 2012Publication date: May 29, 2014Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Jiancun Zhang, Yingjun Zhang, Hongming Xie, Qingyun Ren, Huichao Luo, Tianzhu Yu, Yumei Tan
-
Publication number: 20140056849Abstract: The present invention provides substituted azaindole prodrugs, methods of making said prodrugs, pharmaceutical compositions of said prodrugs and methods of using said prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as cancer.Type: ApplicationFiled: August 26, 2013Publication date: February 27, 2014Applicants: Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLCInventors: Ning Xi, Tingjin Wang, Yin Tang, Mingming Sun, Qian Wang
-
Patent number: 8436154Abstract: The present invention provides an erythromycin crystallizing method, which comprises using dichloromethane containing solvent as a preparation solvent, and the dichloromethane solution of erythromycin received was gradiently cooled from high temperature down to low temperature, and thus making erythromycin crystallize. According to the method of the present invention, the content of erythromycin A is high, the content of erythromycin A in the erythromycin crystalline is more than 94.5% (HPLC detection method), the content of dichloromethane in the erythromycin crystalline is less than 600 ppm, the content of water in the erythromycin crystalline is less than 2.5%, the microbiological titre of the erythromycin crystalline is more than 940 ?/mg.Type: GrantFiled: October 29, 2009Date of Patent: May 7, 2013Assignee: Sunshine Lake Pharma Co., Ltd.Inventors: Xiaoping Ma, Luning Song
-
Patent number: 8426585Abstract: The present invention provides novel compounds useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.Type: GrantFiled: August 17, 2012Date of Patent: April 23, 2013Assignees: Sunshine Lake Pharma Co., Ltd.Inventor: Ning Xi
-
Patent number: 8343969Abstract: This invention relates to a bromo-phenyl substituted thiazolyl dihydropyrimidine, its preparation method and use as a medicament for treating and preventing hepatitis B infections. The invention also relates to a composition comprising the dihydropyrimidine, one or more antiviral agents and, optionally, an immunomodulator for treating and preventing HBV infections.Type: GrantFiled: July 17, 2012Date of Patent: January 1, 2013Assignee: Sunshine Lake Pharma Co., Ltd.Inventors: Siegfried Goldman, Jing Li, Yi Song Liu
-
Publication number: 20120315247Abstract: The present invention provides novel compounds useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.Type: ApplicationFiled: August 17, 2012Publication date: December 13, 2012Applicants: SUNSHINE LAKE PHARMA CO., LTD.Inventor: Ning Xi
-
Publication number: 20120282221Abstract: This invention relates to a bromo-phenyl substituted thiazolyl dihydropyrimidine, its preparation method and use as a medicament for treating and preventing hepatitis B infections. The invention also relates to a composition comprising the dihydropyrimidine, one or more antiviral agents and, optionally, an immunomodulator for treating and preventing HBV infections.Type: ApplicationFiled: July 17, 2012Publication date: November 8, 2012Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Goldmann SIEGFRIED, Jing LI, Yi Song LIU
-
Patent number: 8293897Abstract: The present invention provides novel compounds useful in modulating the protein tyrosine kinase activity, and in modulating inter—and/or intra—cellular signaling. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.Type: GrantFiled: October 9, 2009Date of Patent: October 23, 2012Assignees: Sunshine Lake Pharma Co., Ltd.Inventor: Ning Xi
-
Patent number: 8236797Abstract: This invention relates to a bromo-phenyl substituted thiazolyl dihydropyrimidine, its preparation method and use as a medicament for treating and preventing hepatitis B infections. The invention also relates to a composition comprising the dihydropyrimidine, one or more antiviral agents and, optionally, an immunomodulator for treating and preventing HBV infections.Type: GrantFiled: June 18, 2008Date of Patent: August 7, 2012Assignee: Sunshine Lake Pharma Co., Ltd.Inventors: Siegfried Goldmann, Jing Li, Yi Song Liu
-
Patent number: RE44987Abstract: This invention relates to a bromo-phenyl substituted thiazolyl dihydropyrimidine, its preparation method and use as a medicament for treating and preventing hepatitis B infections. The invention also relates to a composition comprising the dihydropyrimidine, one or more antiviral agents and, optionally, an immunomodulator for treating and preventing HBV infections.Type: GrantFiled: April 25, 2013Date of Patent: July 1, 2014Assignee: Sunshine Lake Pharma Co., Ltd.Inventors: Siegfried Goldmann, Jing Li, Yi Song Liu
-
Patent number: RE45004Abstract: This invention relates to a bromo-phenyl substituted thiazolyl dihydropyrimidine, its preparation method and use as a medicament for treating and preventing hepatitis B infections. The invention also relates to a composition comprising the dihydropyrimidine, one or more antiviral agents and, optionally, an immunomodulator for treating and preventing HBV infections.Type: GrantFiled: April 24, 2013Date of Patent: July 8, 2014Assignee: Sunshine Lake Pharma Co., Ltd.Inventors: Siegfried Goldmann, Jing Li, Yi Song Liu